Sparfosic acid trisodium is a CAD (carbamoyl-phosphate synthetase 2) inhibitor and also an aspartate transcarbamoyl transferase inhibitor with antitumour activity.

Method:
Br-1 and L-2 cell lines, established from metastases in nude mice injected with the human tumor cell line MDA-MB-435, were treated with Sparfosic acid trisodium (300 µM) for 12, 24, and 48 hours to evaluate its effects on the cell cycle.
Result:
Following treatment, both cell lines were predominantly arrested in the S phase, with a slightly higher proportion of S phase cells observed in L-2 compared to Br-1 cells. [1]

Method:
Sparfosic acid trisodium was administered intraperitoneally at a dose of 490 mg/kg on days 1, 5, and 9 to tumor-bearing mice implanted with either B16 melanoma or Lewis lung carcinoma, to evaluate its antitumor efficacy.

Result:
In the B16 melanoma model, Sparfosic acid trisodium extended mouse survival by 77%–86% compared to controls. In the Lewis lung carcinoma model, the compound showed high sensitivity; subcutaneous administration on days 1, 5, and 9 Resulted in a 50% cure rate in tumor-bearing mice. [3]